Details

Autor(en) / Beteiligte

• Arora, Shaily
• Narayan, Preeti
• Osgood, Christy L
• Wedam, Suparna
• Prowell, Tatiana M
• Gao, Jennifer J
• Shah, Mirat
• Krol, Danielle
• Wahby, Sakar
• Royce, Melanie
• Ghosh, Soma
• Philip, Reena
• Ison, Gwynn
• Berman, Tara
• Brus, Christina
• Bloomquist, Erik W
• Fiero, Mallorie H
• Tang, Shenghui
• Pazdur, Richard
• Ibrahim, Amna
• Amiri-Kordestani, Laleh
• Beaver, Julia A

Titel

U.S. FDA Drug Approvals for Breast Cancer: A Decade in Review

Ist Teil von

• Clinical cancer research, 2022-03, Vol.28 (6), p.1072-1086

Ort / Verlag

United States

Erscheinungsjahr

2022

Quelle

MEDLINE

Beschreibungen/Notizen

• Over the last decade, the treatment of patients with breast cancer has been greatly impacted by the approval of multiple drugs and indications. This summary describes 30 FDA approvals of treatments for breast cancer from 2010 to 2020. The trial design endpoints, results, and regulatory considerations are described for each approved indication. Of the 30 indications, 23 (76.6%) received regular and 7 (23.3%) received accelerated approval. Twenty-six approvals were granted in metastatic breast cancer (MBC) and four in early breast cancer. Approval decisions for the 26 MBC indications were initially supported by progression-free survival (PFS) in 21 (80.8%), overall survival (OS) or a combination of OS and PFS in two (7.7%), and objective response rate (ORR) in three (11.5%). The four approvals in early breast cancer utilized pathologic complete response (pCR) in one (25%) and invasive disease-free survival (iDFS) in three (75%) trials. Among the 30 indications, 22 received priority review, seven were granted Breakthrough Therapy Designation, and 10 applications participated in one or more pilot Oncology Center of Excellence regulatory review initiatives, including Real Time Oncology Review, Assessment Aid, and Project Orbis. FDA initiatives to advance breast cancer drug development are also described.